SurModics (SRDX) Receiving Somewhat Favorable Press Coverage, Study Shows
News coverage about SurModics (NASDAQ:SRDX) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. SurModics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 48.091954198692 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern’s rankings:
- SurModics, Inc. (SRDX) Director Susan E. Knight Sells 6,000 Shares (americanbankingnews.com)
- Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International (finance.yahoo.com)
- The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape’s Woes Continue (msn.com)
- SurModics, Inc. (SRDX) VP Joseph J. Stich Sells 2,000 Shares (americanbankingnews.com)
- Surmodics’ (SRDX) IVD Unit Boosts Growth, R&D Focus Solid (finance.yahoo.com)
SurModics stock opened at $71.80 on Tuesday. SurModics has a 52 week low of $25.00 and a 52 week high of $74.10. The company has a market cap of $940.62 million, a price-to-earnings ratio of 140.78, a PEG ratio of 16.38 and a beta of 0.61.
Several equities analysts have commented on SRDX shares. Lake Street Capital lifted their target price on shares of SurModics from $38.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, May 2nd. Barrington Research lifted their target price on shares of SurModics from $22.50 to $43.00 and gave the stock an “outperform” rating in a research report on Thursday, May 3rd. Needham & Company LLC lifted their target price on shares of SurModics from $46.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 16th. BidaskClub raised shares of SurModics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 9th. Finally, ValuEngine raised shares of SurModics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $70.75.
In related news, VP Charles W. Olson sold 20,000 shares of SurModics stock in a transaction that occurred on Thursday, May 24th. The shares were sold at an average price of $48.54, for a total value of $970,800.00. Following the sale, the vice president now owns 33,467 shares of the company’s stock, valued at approximately $1,624,488.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Susan E. Knight sold 6,000 shares of SurModics stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $72.93, for a total transaction of $437,580.00. Following the completion of the sale, the director now directly owns 19,728 shares in the company, valued at approximately $1,438,763.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,000 shares of company stock worth $3,545,630. Insiders own 7.70% of the company’s stock.
SurModics Company Profile
Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.
Featured Article: Investing in Dividend Stocks
Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.